TV3326, a novel neuroprotective drug with cholinesterase and monoamine oxidase inhibitory activities for the treatment of Alzheimer's disease

Journal of Neural Transmission, Supplement

Volumn 60, Issue , 2000, Pages 157-169

  Weinstock, M ^a   Bejar, C ^a   Wang, R H ^a   Poltyrev, T ^a   Gross, A ^b   Finberg, J P M ^b   Youdim, M B H ^b  

^a HEBREW UNIVERSITY   (Israel)

^b TECHNION ISRAEL INSTITUTE OF TECHNOLOGY   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

(N PROPARGYL AMINOINDAN 5 YL)ETHYL METHYLCARBAMATE; (N PROPARGYLAMINOINDAN 5 YL)ETHYL METHYLCARBAMATE; CHOLINESTERASE INHIBITOR; LADOSTIGIL; MONOAMINE OXIDASE B INHIBITOR; NEUROPROTECTIVE AGENT; RASAGILINE; SCOPOLAMINE; TV 1022; TV 2319; TV 2379; TYRAMINE; UNCLASSIFIED DRUG;

ALZHEIMER DISEASE; ANIMAL BEHAVIOR; ANIMAL CELL; ANIMAL MODEL; ANIMAL TISSUE; CHOLINESTERASE INHIBITION; CONFERENCE PAPER; CONTROLLED STUDY; DRUG MECHANISM; DRUG SELECTIVITY; FORCED SWIMMING TEST; MALE; NEUROPROTECTION; NONHUMAN; PASSIVE AVOIDANCE; PRIORITY JOURNAL; RAT; SPATIAL MEMORY;

ACETYLCHOLINESTERASE; ALZHEIMER DISEASE; ANIMALS; BRAIN INJURIES; CHOLINESTERASE INHIBITORS; INDANS; MALE; MEMORY DISORDERS; MONOAMINE OXIDASE; MONOAMINE OXIDASE INHIBITORS; MOTOR ACTIVITY; NEUROPROTECTIVE AGENTS; RATS; RATS, SPRAGUE-DAWLEY; SCOPOLAMINE;

EID: 0034525115     PISSN: 03036995     EISSN: None     Source Type: Journal    
DOI: 10.1007/978-3-7091-6301-6_10     Document Type: Article

References (32)

1. Rasagiline, a monoamine oxidase-B inhibitor, protects NGF-differentiated PC12 cells against oxygen-glucose deprivation
2. Rescue of axotomized immature rat motorneurons by R (-) deprenyl: Stereospecificity and independence from monoamine oxidase inhibition
3. Patterns of memory failure after scopolamine treatment: Implications for cholinergic hypothesis of dementia
4. Effect of of rivastigmine on scopolamine-induced memory impairment in rats
5. Rivastigmine, a brain-selective acetylcholinesterase inhibitor, ameliorates cognitive and motor deficits induced by closed-head injury in the mouse
6. Alzheimer's disease: A disorder of cortical cholinergic innervation
7. Drug choice in depression. Selective serotonin reuptake inhibitors or tricyclic antidepressants?
8. A new and rapid colorimetric determination of acetylcholinesterase activity
9. Pharmacology and neuroprotective properties of rasagiline
10. Increased survival of dopaminergic neurons by rasagiline, a monoamine oxidase B inhibitor
11. Pharmacology of rasagiline (N-propargyl-1R-aminoindan)
12. L-deprenyl in Alzheimer's disease: Cognitive and behavioral effects
13. Evidence for neuronal oxidative damage in Alzheimer's disease
14. Analysis of acetylcholine release following concussive brain injury in the rat
15. Neuroprotective effect of rasagiline, a selective MAO-B inhibitor, against closed head injury in the mouse
16. Selective acetylenic suicide and reversible inhibitors of monoamine oxidase type A and type B
17. Effects of antidepressants in the rat forced swim test
18. Glyceraldehyde-3-phosphate dehydrogenase, the putative target of the anti-apoptotic compounds CGP 3466 and R-(-)deprenyl
19. L-Deprenyl reduces brain damage in rats exposed to transient hypoxia-ischemia
20. Selegiline treatment after transient global ischemia in gerbils enhances the survival of CA1 pyramidal cells in the hippocampus
21. An attempt to dissociate "spatial-mapping" and "working memory" theories of hippocampal function
22. Development of a water maze procedure for studying spatial learning in the rat
23. The prevalence of depression in Alzheimer's disease and vascular dementia in a population sample
24. Possible neurotransmitter basis of behavioral changes in Alzheimer's disease
25. Behavioral despair in rats: A new model sensitive to antidepressant treatments
26. Increased monoamine oxidase B activity in plaque-associated astrocytes of Alzheimer brains revealed by quantitative radioautography
27. Intestinal metabolism of tyramine by both forms of monoamine oxidase in the rat
28. Assay of monoamine oxidase
29. Selectivity of cholinesterase inhibition: Clinical implications for the treatment of Alzheimer's disease
30. Neuroprotective properties of the antiparkinson drug rasagiline and its optical S-isomer
31. Novels drugs possessing both cholinesterase and monoamine oxidase inhibitory activities
32. Immunocytochemical evidence of neuroprotection by R(-)-deprenyl and N-(2-hexyl)-N-methylpropargylamine on DSP-4-induced degeneration of rat brain noradrenergic axons and terminals